SynthesisInternational journal of molecular sciences2026
Artificial Intelligence in Chronic Rhinosinusitis: From Molecular Profiling to Personalized Clinical Management-A Systematic Review.
Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease imposing a substantial health and economic burden. Artificial intelligence (AI) has emerged as a promising tool to address CRS complexity in both clinical and research settings. We conducted a systematic review following PRISMA guidelines, searching PubMed, Web of Science, and Embase for peer-reviewed articles utilizing machine learning, deep learning, and natural language processing, with a focus on molecular-level or immunologic mechanisms in CRS. Thirty-one studies were included in the qualitative synthesis. Our results demonstrate that while AI-driven analysis helps stratify patient endotypes, the identified schemes exhibit substantial heterogeneity in cluster numbers and features, raising concerns about their reproducibility. AI applications also included histopathological image interpretation, drug discovery, biologic therapy selection, and prognostic modeling to evaluate revision surgery risks and olfactory dysfunction. However, using the PROBAST+AI framework, we found that 87.1% of the assessed studies carry a high overall risk of bias, mainly due to the reliance on apparent performance or internal validation and limited independent evaluation of model performance, indicating that many reported performance estimates may be optimistic. Future large-scale, multicenter collaborations integrating AI into clinical workflows will be essential to establish reliable and generalizable AI applications for personalized CRS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.